THC Pain-Behavior Effects and CBD Serum-Cytokine Changes Diverged in Rats

A change in an inflammatory marker is not automatically a change in pain. In rats with experimentally induced inflammation, THC and CBD showed different patterns across pain-related behavior, paw swelling and serum cytokines.

The experiment measured several domains

Researchers used an inflammatory-pain model and repeated THC, CBD or vehicle treatment. Outcomes included mechanical and thermal responses, weight bearing, movement and hindpaw edema. A related experiment measured cytokines in serum, a specific processed blood matrix.

Positive and null results pointed in different directions

The abstract reports dose-related reduction of pain-related behaviors with THC, little tolerance over the short regimen and no reduction in paw edema. CBD's effects on pain-related behavior were minimal, although several serum cytokines changed. THC produced little or no change in the measured serum cytokines.

The measurements are not substitutes

Pain-related behavior can improve without a detectable reduction in swelling or the selected circulating markers. Conversely, a cytokine change does not demonstrate meaningful analgesia. Serum measurements also cannot identify every local tissue process or be treated as a measure of THC-related intoxication.

Few sex differences in drug effects were reported, while the inflammatory immune response itself was greater in males in the relevant comparisons. This is a short-term rat study, not proof of comparative efficacy in patients. The defensible interpretation preserves the separate outcomes instead of giving either cannabinoid a single global label such as anti-inflammatory, analgesic or ineffective.

Related: interpreting cannabis tolerance claims.

Research cited

Britch SC; Goodman AG; Wiley JL; Pondelick AM; Craft RM. Antinociceptive and Immune Effects of Delta-9-Tetrahydrocannabinol or Cannabidiol in Male Versus Female Rats with Persistent Inflammatory Pain. The Journal of pharmacology and experimental therapeutics (2020). doi:10.1124/jpet.119.263319. Findings discussed from the study abstract.

Spread the love


The National Black Lawyers

top 40 lawyers

civil trial law

Lawyers of Distinction

Loading...

Recent Blog Articles

APD371 Maintained a Pain-Response Effect for Five Days in a Preclinical Development Study

A 2017 drug-discovery report described APD371, a selective CB2 agonist, maintaining its effect during a five-day rat osteoarthritis-pain protocol. That short preclinical finding is different from established long-term clinical efficacy. The report concerned selection of a development candidate The authors considered receptor efficacy, pharmacokinetics and pharmaceutical properties alongside an oral…

Spread the love

Read Article: APD371 Maintained a Pain-Response Effect for Five Days in a Preclinical Development Study

Two Biased CB2 Agonists Had Different Durability in a Rat Osteoarthritis Experiment

A 2021 rat study found sustained pain-response effects with JWH133 while another CB2 agonist lost efficacy after two days under its repeated-treatment protocol. Shared receptor targeting did not establish equal durability. The compounds were compared in a defined model The experiment used chemically induced osteoarthritis and measured pressure responses and…

Spread the love

Read Article: Two Biased CB2 Agonists Had Different Durability in a Rat Osteoarthritis Experiment

An Acute Cannabis Review Treated Neurocognitive Response as a Multi-Factor Question

A 2021 review argued that acute neurocognitive responses to cannabis vary with biological, pharmacological and exposure-related factors. A product label or use-frequency category alone cannot capture all the determinants discussed. The review considered interacting sources of variation It discussed brain-network activity, formulation, use frequency and differences between therapeutic and recreational…

Spread the love

Read Article: An Acute Cannabis Review Treated Neurocognitive Response as a Multi-Factor Question

Speak with an expert today!

Contact the offices of Okorie Okorocha for professional and reliable advice which you can trust.

Call (424) 363-3347 Contact Us